低剂量秋水仙碱在2型糖尿病合并近期心肌梗死患者中的应用:COLCOT研究
COLCOT是一项随机双盲试验,在心肌梗死后30天内启动秋水仙碱0.5 mg每日一次或安慰剂治疗。预设分析纳入959例2型糖尿病患者,中位随访22.6个月。秋水仙碱组主要终点事件发生率为8.7%,安慰剂组为13.1%(HR 0.65;95%CI 0.44-0.96;P=0.03)。
要点
- 2型糖尿病合并近期心肌梗死患者中,秋水仙碱0.5 mg每日一次较安慰剂降低主要终点事件(HR 0.65;95%CI 0.44-0.96;P=0.03)。
- 秋水仙碱组恶心发生率2.7% vs 安慰剂组0.8%(P=0.03),肺炎发生率2.4% vs 0.4%(P=0.008)。
- 作者认为结果支持在初级预防中开展COLCOT-T2D试验。
核心结论
- 在2型糖尿病合并近期心肌梗死患者中,秋水仙碱0.5 mg每日一次可大幅减少心血管事件。
- 作者认为这些结果支持在初级预防中开展COLCOT-T2D试验。
研究设计与样本
- COLCOT为随机双盲试验,比较秋水仙碱0.5 mg每日一次与安慰剂,在心肌梗死后30天内启动。
- 本分析为预设分析,纳入959例2型糖尿病患者,中位随访22.6个月。
主要发现
- 主要终点事件在秋水仙碱组发生8.7%,安慰剂组发生13.1%(HR 0.65;95%CI 0.44-0.96;P=0.03)。
- 恶心在秋水仙碱组报告2.7%,安慰剂组报告0.8%(P=0.03)。
- 肺炎在秋水仙碱组发生2.4%,安慰剂组发生0.4%(P=0.008)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The cardiovascular benefits of low-dose colchicine have been demonstrated in patients with coronary disease. Its effects were evaluated in this prespecified analysis in patients with type 2 diabetes (T2D) from the Colchicine Cardiovascular Outcomes Trial (COLCOT). RESEARCH DESIGN AND METHODS: COLCOT was a randomized, double-blinded trial of colchicine, 0.5 mg daily, versus placebo initiated within 30 days after a myocardial infarction. RESULTS: There were 959 patients with T2D enrolled and monitored for a median of 22.6 months. A primary end point event occurred in 8.7% of patients in the colchicine group and in 13.1% in the placebo group (hazard ratio 0.65; 95% CI 0.44-0.96; P = 0.03). Nausea was reported in 2.7% and 0.8% in the study groups (P = 0.03), and pneumonia occurred in 2.4% and 0.4% (P = 0.008). CONCLUSIONS: Among patients with T2D and a recent myocardial infarction, colchicine, 0.5 mg daily, leads to a large reduction of cardiovascular events. These results support the conduct of the COLCOT-T2D trial in primary prevention.
引用
- Roubille F, Bouabdallaoui N, Kouz S, et al. Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. 2024. PMID: 38181203. doi:10.2337/dc23-1825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。